1. Introduction {#s0005}
===============

Osteosarcoma is the most common primary malignant tumors of bone [@b0005]. Epidemiological data showed that there were two peaks of incidence in osteosarcoma patients, particularly among early adolescence aged 15--19 years [@b0010]. In recent years, patients' age with osteosarcoma is increasing [@b0015] and patients over the age of 40 years account for 13--30% of all patients with osteosarcoma [@b0020]. According to epidemiological data, osteosarcoma is the eighth leading cancer with an incidence of 4.4 per million, mainly occurring in adolescents and adults [@b0025]. Despite substantial progress achieved in diagnosis and treatment for osteosarcoma in the past decades, the overall 5-year survival remains unsatisfactory for local relapse or metastasis after surgical resection of primary osteosarcoma.

The poor clinical prognosis of osteosarcoma partially results from lack of a good indicator to detect tumors at an early stage. Furthermore, the ability to predict the prognosis of a patient is indispensable for selecting the optimal treatment plan and follow-up strategies. Although prognostic indicators are the Enneking surgical criteria [@b0030] and alkaline phosphatase, heterogeneous clinical outcomes are frequently found within the same tumor stage. Therefore, it is necessary for us to further understand the underlying mechanisms and find a dependable indicator of osteosarcoma to predict clinical outcome.

Recently, the emerging evidence revealed that the systemic inflammatory response has been reported to be an independent prognostic biomarker in various types of tumor [@b0035; @b0040]. Published evidence has shown a significant link between inflammatory markers and poor prognosis in several types of tumors, including thrombocytosis, leukocytosis, high neutrophil-to-lymphocyte ratio (NLR) or platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) [@b0045; @b0050; @b0055; @b0060; @b0065]. However, the influence of LMR on the prognosis of osteosarcoma patient has been not reported. Herein, the purpose of this study was to estimate the influence of LMR on clinical prognosis in 327 osteosarcoma patients at post-operation.

2. Materials and methods {#s0010}
========================

2.1. Patients {#s0015}
-------------

The Medical Ethics Committee of The First People's Hospital of Anqing approved this study. Written informed consents were obtained from all eligible patients. Medical records of all newly diagnosed osteosarcoma patients between 2006 and 2010 in The First People's Hospital of Anqing and The Second People's Hospital of Lianyungong were reviewed and retrospectively analyzed in the present study. The diagnosis of osteosarcoma was confirmed depended on histological evidence and classified on the basis of the Enneking surgical criteria [@b0030]. The inclusion criteria were as follows: (1) no prior pre-operative anticancer treatment, such as chemotherapy, blood transfusion, and radiotherapy. (2) All patients with osteosarcoma underwent surgical resection. (3) No hematology disease, infection and hyperpyrexia. (4) Informed consents were obtained. Finally, 327 patients were enrolled in the present study. Clinical features of eligible patients were collected including age, sex, tumor location, pathological fracture, alkaline phosphatase (ALP), clinical stage, metastasis at diagnosis and post-operative chemotherapy.

2.2. Blood sample analysis {#s0020}
--------------------------

Blood samples were obtained for the measurement of lymphocyte and monocyte counts at pre-operation.

2.3. Definition and optimal cut-off value of LMR {#s0025}
------------------------------------------------

LMR was defined as the lymphocyte counts divided by the monocyte counts. Using overall survival (OS), as end-point, the optimal cut-off value of LMR was obtained when the Youden index was maximal. Subsequently, patients with a LMR greater than the corresponding cut-off value were defined as high LMR (HLMR), and others were defined as low LMR (LLMR).

2.4. Patient follow-up {#s0030}
----------------------

Each patient was followed up regularly until death or December 2014 at post-operation. Physical examination, laboratory tests and imageological diagnosis were performed at every visit. The follow-up period varied from 3 months to 5 years, with a median of 24 months. OS was calculated from the data of surgical resection to the data of death. Event free survival (EFS) was calculated from the data of surgical resection to the data of disease relapse, progression or tumor-related death. The date of last follow-up was used for drop-out patients.

2.5. Statistical analysis {#s0035}
-------------------------

To evaluate the sensitivity and specificity of the 5-year OS, the receiver operating characteristic (ROC) curve was applied and Youden index was estimated to determine the optimal LMR cut-off value. Comparison of categorical variables was conducted using a Chi-square test. Comparison of continuous variables was conducted using a Student's *t* test. Survival curves were plotted by the Kaplan--Meier method and the significance was assessed by the log-rank test. Significant predictors for OS and EFS determined by univariate analysis were evaluated by multivariate analysis using Cox's proportional hazards model. Nomogram for OS was performed by R 3.0.3 software using the package of *rms* (Institute for Statistics and Mathematics, Austria). A final model selection was performed by a backward step-down selection process, and Harrell's concordance index (*c*-index) was applied to evaluate the predictive accuracy. All results analyses were conducted by SPSS 17.0 software (IBM, USA). *P* values less than 0.05 were considered statistically significant.

3. Result {#s0040}
=========

3.1. Clinicopathologic characteristics {#s0045}
--------------------------------------

Of 327 patients with osteosarcoma, 235 (71.9%) were male, and the mean age was 20 years (range 10--44 years; [Table 1](#t0005){ref-type="table"}). The medians of lymphocyte counts and monocyte counts were 1220 and 340 per μL, respectively. 130 (39.8%) patients with initial metastasis and 58 (17.7%) patients with pathological fracture were recorded from newly diagnosed patients. According to Enneking surgical staging criteria, the number of stage I--II and III was 168 (51.4%) and 159 (48.6%), respectively. Pathological results suggested that 267 (81.7%) patients' osteosarcomas were located in the tibia or femur. During the follow-up period, 166 (50.8%) patients had experienced systemic chemotherapy. Among all enrolled patients, 184 (56.3%) patients died from cancer-related disease, and 217 (66.4%) patients experienced disease relapse, progression or tumor-related death.

3.2. The optimal cut-off value for LMR {#s0050}
--------------------------------------

The areas under the curve (AUC) for LMR were 0.665 (*P *\< 0.001, [Fig. 1](#f0005){ref-type="fig"}), when the OS was employed as end-point for LMR. The optimal cut-off value was 3.43 for LMR. All patients were divided into two groups with the high group that ⩾ the cut-off value (HLMR) and the low group less than the cut-off value (LLMR) on the basis of the optimal cut-off value.

3.3. The associations of LMR with clinicopathologic features {#s0055}
------------------------------------------------------------

To explore associations of LMR with clinicopathologic features of osteosarcoma patients, comparisons between the high and low groups for LMR were carried out ([Table 1](#t0005){ref-type="table"}). Our results indicated that young age, elevated ALP, metastasis at diagnosis, chemotherapy, lymphocyte counts and monocyte counts were significantly associated with LMR (*P *\< 0.05). However, patients' sex, tumor location, pathological fracture and clinical stage were not found to be associated with LMR.

3.4. Prognostic factors for OS and EFS {#s0060}
--------------------------------------

The Kaplan--Meier curve showed that the 5-year OS rates of the LLMR group were significantly lower than those of the HLMR group (*P *\< 0.001; [Fig. 2](#f0010){ref-type="fig"}A), and similar result was also observed in the 5-year EFS rates (*P *\< 0.001; [Fig. 2](#f0010){ref-type="fig"}B). Subsequently, univariate analyses indicated that advanced clinical stage, metastasis at diagnosis, chemotherapy and LLMR were closely correlated with poor prognosis. Furthermore, multivariate analyses of OS and EFS were performed including age, sex and clinical variables with univariate log-rank *P *\< 0.05: advanced clinical stage, metastasis at diagnosis, chemotherapy and LLMR. LLMR, advanced clinical stage and metastasis emerged as markers for shorter OS and EFS ([Table 2](#t0010){ref-type="table"}), and were considered as independent prognostic indicators for patients with osteosarcoma.

3.5. Prognostic nomogram for OS {#s0065}
-------------------------------

To further predict the overall survival of osteosarcoma patients after surgical resection, a predictive model was constructed by Cox regression model analysis using all the significant independent risk factors for OS ([Fig. 3](#f0015){ref-type="fig"}). It can predict the probability of death of osteosarcoma within 3 or 5 years after operation, assuming the patient does not die of another cause first. The c-index for OS prediction was 0.630.

4. Discussion {#s0070}
=============

We investigated the influence of LMR on clinical prognosis of patients with osteosarcoma which has reflected a systemic inflammatory response. The pre-operative LLMR in the peripheral blood of osteosarcoma patients was significantly associated with poor prognosis following surgery. Despite advanced progress in the understanding of the association between inflammatory biomarkers and prognosis of various cancers [@b0035; @b0070; @b0075; @b0080], the impact of inflammatory markers on clinical prognosis of osteosarcoma patients remains confused. Herein, this current study was the first attempt to evaluate the prognosis of patients with osteosarcoma based on LMR in the peripheral blood and establish a predictive model to improve the predictive accuracy. As the peripheral blood cell counts test is routinely performed without need for additional effort in all patients with cancer, it is a simple, reproducible, and inexpensive parameter of the inflammatory response as well as a prognostic biomarker. Interestingly, LMR could be considered as an independent indicator for both OS and EFS by multivariate analyses.

Rudolf Virchow et al*.* first showed that "lymphoreticular infiltrate" could reflect the origin of tumor at the sites of chronic inflammation [@b0085]. Over the past decades, Virchow's hypothesis was proved by the emerging studies, revealing the impact of inflammatory microenvironment on tumor. The inflammatory response, which is implicated in repair of tissue damage due to tumors, is an indispensable factor in the tumor cell microenvironment [@b0090; @b0095]. Hence, inflammatory cells participate in tumor proliferation, invasion, migration, angiogenesis and metastasis. Meanwhile, tumors could result from inflammatory sites, possibly by the recruitment of inflammatory cells, chemokines and cytokines. Therefore, the adaptive immune system may be converted, and this inflammatory response reactivates tumor development and progression. The inflammatory response could cause leukocytosis and lymphocytopenia [@b0100]. The lymphocyte response plays a critical role in the suppression of tumor progression [@b0105]. The possible mechanisms underlying neutrophilia in tumor progression and metastasis are the release of reactive oxygen species or nitric oxide and remodeling of the extracellular matrix [@b0110]. Hence, better understanding of the links between inflammation and tumor contributes to the treatment and prevention of tumor. Various biomarkers have been reported to reflect the association of inflammation and tumor, such as interferon-gamma/interleukin-4 ratio [@b0115] and inflammation-based prognostic score on the basis of CRP and albumin levels [@b0120]. The systemic inflammatory marker (LMR) may be also considered as potential prognostic factors for various types of tumors. Chen et al. reported that a decreased pretreatment LMR is associated with a poor prognosis in cervical cancer patients [@b0065]. Jiang et al. used pretreatment LMR as an independent prognostic factor in patients with metastatic nasopharyngeal carcinoma [@b0125]. Zhang et al. found that pre-operative LMR is a better prognostic factor in bladder cancer patients undergoing radical cystectomy [@b0130].

Little evidence has shown that LMR is associated with prognosis in osteosarcoma. Our study was first attempt to evaluate the influence of LMR on prognosis of 327 osteosarcoma patients and establish a predictive model to improve the predictive accuracy for 3-year and 5-year overall survival. Similar to other results in various cancers, pre-operative LLMR was significantly associated with poor prognosis. Interestingly, a decreased pre-operative LMR could be regarded as an independent prognostic factor for both OS and EFS in patients with osteosarcoma. Our constructed nomogram performed well in the prediction of overall survival (*c*-index 0.630). These data supported that the nomogram could better predict prognosis in osteosarcoma patients at post-operation.

Some limitations of our study should be acknowledged. Firstly, the study was a retrospective design, with a small population size of 327 patients, which resulted in no significant association between clinical prognosis and chemotherapy. Secondly, the peripheral blood findings were not compared with findings of peritumoral inflammation in the primary osteosarcoma tissue. Nevertheless, data in peripheral blood provided a novel horizon to understand the role of LMR in the development and progression of osteosarcoma. Finally, some heterogeneities were appeared in the treatment of osteosarcoma patients at post-operation, which resulted in different clinical prognosis. Hence, further prospective studies are necessary to illuminate the relationship between LMR and prognosis for patients with osteosarcoma.

In summary, the pre-operative LMR is associated with clinical prognosis of patients with osteosarcoma. Integrate LMR and the prognostic nomogram may be used to evaluate clinical prognosis and offer appropriate therapeutic strategy. In future, a prospective and well-designed study of LMR is warranted for further identification of our findings.
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![ROC curves for LMR. The optimal cut-off level of LMR was determined based on the largest of sensitivity and specificity by receiver operating characteristic curve (ROC) analysis for overall survival.](gr1){#f0005}

![Kaplan--Meier curves for survival probability according to LMR levels. (A) Patients with LMR ⩽ 3.43 had a significantly associated with worse overall survival than those with LMR \> 3.43; (B) patients with LMR ⩽ 3.43 had a significantly associated with worse event free survival than those with LMR \> 3.43.](gr2){#f0010}

![Postoperative nomogram with LMR and significant clinicopathologic characteristics predicted the probability of osteosarcoma for overall survival. To use it, an individual patient's value is located on each variable axis, and a line is drawn upward to determine the number of points received for each variable parameter. The sum of these points is located on the Total Points axis, and a line is drawn downward to the survival axes to determine the probability of 3- or 5-year survival.](gr3){#f0015}

###### 

Association of the patients' clinical parameters with LMR.

  Clinical parameters                                             Total *N* = 327 (%)   LMR                 *P*                 
  --------------------------------------------------------------- --------------------- ------------------- ------------------- -------
  Age (year)                                                                                                                    
   $\leqq$20                                                      217 (66.4%)           144 (74.2%)         73 (54.9%)          0.000
   \>20                                                           110 (33.6%)           50 (25.8%)          60 (45.1%)          
                                                                                                                                
  Sex                                                                                                                           
   Male                                                           235 (71.9%)           145 (44.3%)         90 (67.7%)          0.162
   Female                                                         92 (28.1%)            49 (55.7%)          43 (33.3%)          
                                                                                                                                
  Tumor location                                                                                                                
   Tibia/femur                                                    267 (81.7%)           152 (78.4%)         115 (86.5%)         0.063
   Elsewhere                                                      60 (18.3%)            42 (21.6%)          18 (13.5%)          
                                                                                                                                
  Pathological fracture                                                                                                         
   Yes                                                            58 (17.7%)            32 (16.5%)          26 (19.5%)          0.478
   No                                                             269 (82.3%)           162 (83.5%)         107 (80.5%)         
                                                                                                                                
  ALP                                                                                                                           
   Elevated                                                       147 (45.0%)           97 (50.0%)          50 (37.6%)          0.027
   Normal                                                         180 (55.0%)           97 (50.0%)          83 (62.4%)          
                                                                                                                                
  Clinical stage[a](#tblfn1){ref-type="table-fn"}                                                                               
   I--II                                                          168 (51.4%)           92 (47.4%)          76 (57.1%)          0.084
   III                                                            159 (48.6%)           102 (52.6%)         57 (42.9%)          
                                                                                                                                
  Metastasis at diagnosis                                                                                                       
   Present                                                        130 (39.8%)           98 (50.5%)          32 (24.1%)          0.000
   Absent                                                         197 (60.2%)           96 (49.5%)          101 (75.9%)         
                                                                                                                                
  Chemotherapy                                                                                                                  
   Yes                                                            166 (50.8%)           77 (39.7%)          89 (66.9%)          0.000
   No                                                             161 (49.2%)           117 (60.3%)         44 (33.1%)          
                                                                                                                                
  Lymphocyte counts (10^3^/μL)[b](#tblfn2){ref-type="table-fn"}   1.22 (0.08--4.85)     1.57 (0.60--4.83)   0.91 (0.09--4.44)   0.000
                                                                                                                                
  Monocyte counts (10^3^/μL)[b](#tblfn2){ref-type="table-fn"}     0.34 (0.02--1.76)     0.34 (0.02--1.76)   0.31 (0.03--0.88)   0.000

ALP, alkaline phosphatase; LMR, lymphocyte-to-monocyte ratio; HLMR, high LMR; LLMR, low LMR.

Clinical stage according to Enneking surgical stage.

Median (range).

###### 

Univariate and multivariate analyses of clinical parameters for the prediction of overall survival and event free survival.

  Clinical parameters                               Overall survival    Event free survival                                                                                       
  ------------------------------------------------- ------------------- --------------------- ------------------- ----------- ------------------- ----------- ------------------- -----------
  Age (year)                                                                                                                                                                      
   $\leqq$20                                        1                                         1                               1                               1                   
   \>20                                             0.82 (0.60--1.12)   0.211                 0.85 (0.62--1.16)   0.309       0.87 (0.66--1.15)   0.328       0.92 (0.69--1.23)   0.575
                                                                                                                                                                                  
  Sex                                                                                                                                                                             
   Male                                             1                                         1                               1                               1                   
   Female                                           0.85 (0.61--1.18)   0.336                 1.00 (0.71--1.40)   0.991       0.92 (0.68--1.24)   0.586       0.94 (0.69--1.27)   0.666
                                                                                                                                                                                  
  Tumor location                                                                                                                                                                  
   Tibia/femur                                      1                                                                         1                                                   
   Elsewhere                                        0.83 (0.58--1.19)   0.313                                                 0.77 (0.55--1.07)   0.113                           
                                                                                                                                                                                  
  Pathological fracture                                                                                                                                                           
   Yes                                              1                                                                         1                                                   
   No                                               0.95 (0.65--1.37)   0.765                                                 0.94 (0.66--1.32)   0.706                           
                                                                                                                                                                                  
  ALP                                                                                                                                                                             
   Normal                                           1                                                                         1                                                   
   Elevated                                         1.04 (0.77--1.39)   0.810                                                 1.01 (0.78--1.32)   0.925                           
                                                                                                                                                                                  
  Clinical stage[a](#tblfn9){ref-type="table-fn"}                                                                                                                                 
   I--II                                            1                                         1                               1                               1                   
   III                                              1.59 (1.19--2.12)   **0.002**             1.44 (1.08--1.93)   **0.015**   1.46 (1.08--1.83)   **0.013**   1.21 (1.01--1.59)   **0.027**
                                                                                                                                                                                  
  Metastasis at diagnosis                                                                                                                                                         
   Absent                                           1                                         1                               1                               1                   
   Present                                          3.75 (2.76--5.10)   **0.000**             2.56 (1.73--3.80)   **0.000**   3.87 (3.17--4.79)   **0.000**   2.90 (2.31--3.75)   **0.001**
                                                                                                                                                                                  
  Chemotherapy                                                                                                                                                                    
   Yes                                              1                                         1                               1                               1                   
   No                                               1.95 (1.45--2.61)   **0.000**             1.27 (0.93--1.74)   0.140       2.73 (2.32--3.27)   **0.000**   1.32 (1.00--1.76)   0.054
                                                                                                                                                                                  
  LMR                                                                                                                                                                             
   HLMR                                             1                                         1                               1                               1                   
   LLMR                                             2.97 (2.16--4.08)   **0.000**             1.72 (1.14--2.60)   **0.010**   3.49 (2.86--4.32)   **0.000**   1.89 (1.32--2.57)   **0.009**

ALP, alkaline phosphatase; LMR, lymphocyte -to-monocyte ratio; HLMR, high LMR; LLMR, low LMR; HR, hazard ratio; CI, confidence interval.

Statistically significant results were in bold.

Clinical stage according to Enneking surgical stage.
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